Vivus Submits Document to FDA
Vivus (NASDAQ: VVUS), the Mountain View, CA-based based obesity drug developer, said today it has submitted a briefing document to the FDA to answer questions the agency raised when it turned down the company’s new drug application in October. The company said it has also gotten a meeting scheduled with the FDA for late January to discuss what would need to be part of its resubmitted application for phentermine/topiramate (Qnexa).
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.